Initial Results from Novavax’ COVID-19-Influenza Vaccine Trial are First to Show Feasibility of Combination Vaccine
Phase 1/2 clinical trial of COVID-19-Influenza combination vaccine candidate indicates vaccine is well-tolerated and immunogenic Data from this combination trial will inform planned Phase 2 dose confirmation trial, scheduled to begin by the end of 2022 Immune response confirmed in stand-alone influenza vaccine and combination vaccine with potential path forward for both Novavax, Inc. (Nasdaq: NVAX), […]